New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AbbVie Inc.

ABBV

Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.

Revenue
+10.3%
EPS
+2,270.0%
Free cash flow
+9.97%
Total debt
+17.7%

Quarter to September 2026, against a year earlier

288.50 4.99 +1.76%
Market cap
$501.2B
P/E
48.8×
Fwd P/E FY26e
37.6×
Dividend yield
2.44%
F-score
8/9
ROIC
20.2%
Net debt / EBITDA
2.6×
Payout ratio
1.2×

AbbVie Inc. (ABBV) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by products and services, and margins
Skyrizi 17,562 28.71%
Rinvoq 8,304 13.58%
Humira 4,540 7.42%
Botox Therapeutic 3,769 6.16%
Vraylar 3,621 5.92%
Imbruvica 2,869 4.69%
Venclexta 2,792 4.57%
All other 2,627 4.30%
Botox Cosmetic 2,602 4.25%
Other, not broken out 1,545 2.53%
Mavyret 1,317 2.15%
Ubrelvy 1,271 2.08%
Other Aesthetics 1,265 2.07%
Qulipta 1,036 1.69%
Other Eye Care 1,009 1.65%
Juvederm Collection 993 1.62%
Linzess 907 1.48%
Elahere 690 1.13%
Ozurdex 493 0.81%
Vyalev 482 0.79%
Lumigan/Ganfort 410 0.67%
Duodopa 381 0.62%
Epkinly 271 0.44%
Other Neuroscience 207 0.34%
Alphagan/Combigan 197 0.32%
Gross margin 70.24%
Operating margin 24.65%
Pre-tax margin 10.79%

Revenue by product or service $m

Line FY2025 FY2024 FY2023 FY2022 FY2015 FY2014 FY2013 FY2012 FY2011
Skyrizi 17,562 11,718 7,763 5,165 — — — — —
Rinvoq 8,304 5,971 3,969 2,522 — — — — —
Humira 4,540 8,993 14,404 21,237 14,012 12,543 10,659 9,265 7,932
Botox Therapeutic 3,769 3,283 2,991 2,719 — — — — —
Vraylar 3,621 3,267 2,759 2,038 — — — — —
Imbruvica 2,869 3,347 3,596 4,568 754 0 — — —
Venclexta 2,792 2,583 2,288 2,009 — — — — —
All other 2,627 3,032 3,035 4,137 1,402 1,957 1,666 1,525 1,735
Botox Cosmetic 2,602 2,720 2,682 2,615 — — — — —
Mavyret 1,317 1,311 1,430 1,541 — — — — —
Ubrelvy 1,271 1,006 815 680 — — — — —
Other Aesthetics 1,265 1,279 1,234 1,290 — — — — —
Qulipta 1,036 658 408 158 — — — — —
Other Eye Care 1,009 1,071 1,239 747 — — — — —
Juvederm Collection 993 1,177 1,378 1,428 — — — — —
Linzess 907 954 1,108 1,035 — — — — —
Elahere 690 479 0 0 — — — — —
Ozurdex 493 494 472 428 — — — — —
Vyalev 482 99 3 — — — — — —
Lumigan/Ganfort 410 429 432 514 — — — — —
Duodopa 381 447 468 458 231 220 178 149 125
Epkinly 271 146 31 — — — — — —
Other Neuroscience 207 239 273 475 — — — — —
Alphagan/Combigan 197 248 272 346 — — — — —
Restasis — — — 666 — — — — —
Hcv — — — — 1,639 48 — — —
Lupron — — — — 826 778 785 800 810
Synthroid — — — — 755 709 622 551 522
Synagis — — — — 740 835 827 825 775
Kaletra — — — — 700 870 962 1,013 1,170
Andro Gel — — — — 694 934 1,035 1,152 874
Creon — — — — 632 516 412 353 332
Sevoflurane — — — — 474 550 568 602 665
Dyslipidemia Products — — — — — — 1,076 2,145 2,504
Other, not broken out 1,545 1,383 1,268 1,278 — — — — —
Revenue 61,160 56,334 54,318 58,054 22,859 19,960 18,790 18,380 17,444

Revenue by region $m

Line FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
United States 46,603 43,029 41,883 45,713 43,510 34,879 23,907 21,524 18,251 15,947 13,561 10,845 10,181 10,435 9,712
All other countries 5,759 5,449 5,042 4,837 4,761 3,977 3,566 3,863 4,080 3,885 4,001 3,896 3,671 2,776 2,674
Germany 1,738 1,465 1,266 1,340 1,223 1,049 909 1,292 1,157 1,104 1,082 1,035 911 756 701
Japan 1,274 1,122 1,008 956 1,090 1,198 1,211 1,591 764 770 599 581 625 718 616
Canada 1,222 1,088 1,076 1,159 1,397 1,159 813 730 659 624 551 551 538 500 446
China 1,006 917 950 912 857 471 195 152 — — — — — — —
France 806 776 780 787 936 797 695 783 730 713 597 584 540 500 516
United Kingdom 626 522 417 462 497 509 372 855 807 776 688 722 606 552 496
Spain 609 528 501 506 519 453 472 611 521 589 618 534 543 525 569
Italy 580 511 484 444 506 379 372 652 475 523 452 432 404 408 428
Brazil 478 464 439 430 368 406 359 350 410 355 376 435 439 434 382
Australia 459 463 472 508 533 527 395 350 — — — — — — —
Netherlands — — — — — — — — 362 352 334 345 332 776 904
Revenue 61,160 56,334 54,318 58,054 56,197 45,804 33,266 32,753 28,216 25,638 22,859 19,960 18,790 18,380 17,444

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.